artemether-lumefantrine

The safety of artemether-lumefantrine in patients with acute, uncomplicated Plasmodium falciparum malaria was investigated prospectively using the auditory brainstem response (ABR) and pure-tone thresholds.

Combining IPTc and HMM can provide significant additional benefit in preventing clinical episodes of malaria as well as anaemia among children in Senegal.

We found no evidence from this trial that zinc supplementation protected against malaria.

This study is the largest data set to date assessing AL therapy for treatment of acute uncomplicated P. falciparum malaria.

Molecular markers for surveillance of Plasmodium falciparum resistance to current antimalarials are sorely needed.

We conducted both pill counts and in-home interviews on medication consumption 72 hours after patients received AL. Complete adherence was defined as correctly taking all 6 AL doses, as assessed by pill count and dose recall. We used logistic regression to identify factors associated with complete adherence.

We compared the prevalence of key pfmdr1 alleles between pretreatment Plasmodium falciparum parasite isolates and parasites that emerged after treatment of uncomplicated malaria in a longitudinal cohort of Ugandan children.

The pharmacokinetic and pharmacodynamic properties of a new pediatric formulation of artemether-lumefantrine, dispersible tablet, were determined within the context of a multicenter, randomized, parallel-group study.

Self-reported malaria was extremely common in this population and adherence to treatment guidelines for the management of malaria in pregnancy was poor.

Programmatic implementation of mRDTs in a moderately endemic area reduced drastically over-treatment with anti-malarials.